Heat Biologics Tightens Belt To Reach Late-2016 Inflection Points
This article was originally published in The Pink Sheet Daily
Executive Summary
Biotech striving to hold on financially until it can deliver top-line data for bladder and lung cancer immunotherapy candidates, but then it will have to content with Roche entering the bladder cancer market with its PD-L1 inhibitor.